Treatment of stable chronic obstructive pulmonary disease

Lancet

Volumn 364, Issue 9436, 2004, Pages 791-802

  Rennard, Stephen I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINOPHYLLINE; ANTIHYPERTENSIVE AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; IPRATROPIUM PLUS SALBUTAMOL; METHYLXANTHINE DERIVATIVE; NICOTINE; NICOTINE GUM; NORTRIPTYLINE; OXITROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BEHAVIOR THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG FATALITY; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HEMATOMA; HUMAN; HYPOKALEMIA; INFLUENZA VACCINATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; PALLIATIVE THERAPY; PATIENT CARE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; SEIZURE; SIDE EFFECT; SMOKING CESSATION; TREMOR; URINE RETENTION; VOMITING; XEROSTOMIA;

EID: 4444331230     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16941-9     Document Type: Conference Paper

References (136)

1. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 160:2000;1683-1689
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ. 51:2002;1-16
3. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995; 107 (suppl): 187-193.
4. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. 1976;Oxford University Press, New York
5. Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 152:1995;S77-120
6. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 8:1995;1398-1420
7. Pauwels R. Global initiative for chronic obstructive lung disease. NIH: 2001; 2701: 1-100. Available at http://www.goldcopd.com (accessed Month XX, Year)
8. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2003. Available at http://www.goldcopd.com (accessed January, 2003).
9. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 23:2004;932-946
10. Davis RM, Novotny TE. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis. 140:1989;82-84
11. 1. JAMA. 272:1994;1497-1505
12. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med. 166:2002;675-679
13. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 161:2000;381-390
14. Buist AS, Sexton GJ, Nagy JM, Ross BB. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis. 114:1976;115-122
15. Wise RA, Kanner RE, Lindgren P, et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest. 124:2003;449-458
16. Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care. 45:2000;1200-1262
17. Rennard SI, Daughton DM. Cigarette smoking and disease. Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM. Pulmonary diseases and disorders. 1998;697-708 McGraw Hill, New York
18. Heishman SJ. Behavioral and cognitive effects of smoking: relationship to nicotine addiction. Nicotine Tob Res. 1:(suppl 2):1999;143-147
19. Henningfield JE, Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther. 234:1985;1-12
20. Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin. 54:2002;36-40
21. Yates SL, Bencherif M, Fluhler EN, Lippiello PM. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or α4β2 receptors to nicotine. Biochem Pharmacol. 50:1995;2001-2008
22. Mumenthaler MS, Taylor JL, O'Hara R, Yesavage JA. Influence of nicotine on simulator flight performance in non-smokers. Psychopharmacology (Berl). 140:1998;38-41
23. Sherwood N. Effects of cigarette smoking on performance in a simulated driving task. Neuropsychobiology. 32:1995;161-165
24. Jo YH, Talmage DA, Role LW. Nicotinic receptor-mediated effects on appetite and food intake. J Neurobiol. 53:2002;618-632
25. Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav. 70:2001;531-549
26. Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport. 13:2002;1097-1106
27. Fiore MC, Bailey WC, Cohen SJ. Smoking cessation. Guideline technical report no. 18. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Publication No. AHCPR 97-Noo4, October, 1997.
28. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update - Health Education Authority. Thorax. 55:2000;987-999
29. Piasecki TM, Fiore MC, McCarthy DE, Baker TB. Have we lost our way? The need for dynamic formulations of smoking relapse proneness. Addiction. 97:2002;1093-1108
30. Irvin JE, Bowers CA, Dunn ME, Wang MC. Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol. 67:1999;563-570
31. Schwartz JL. Review and evaluation of smoking cessation methods: The United States and Canada, 1978-1985. 1987;National Cancer Institute, Bethesda, Maryland
32. Gilpin EA, Pierce JP, Johnson M, Bal D. Physician advice to quit smoking: results from the 1990 California Tobacco Survey. J Gen Intern Med. 8:1993;549-553
33. Silagy C, Stead LF. Physician advice for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Oxford: Update Software.
34. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consulting Clin Psychol. 61:1993;743-750
35. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six-month results from two multicenter controlled clinical trials. JAMA. 266:1991;3133-3138
36. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial - collaborative European anti-smoking evaluation. Eur Respir J. 13:1999;238-246
37. Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tobacco Res. 1:1999;169-174
38. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Preventive Med. 24:1995;41-47
39. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ. 318:1999;285-289
40. Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J. 16:2000;717-722
41. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 337:1997;1195-1202
42. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New Engl J Med. 340:1999;685-691
43. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 357:2001;1571-1575
44. Smith SS, Jorenby DE, Leischow SJ, et al. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob Res. 5:2003;99-109
45. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, 2000. Oxford: Update Software.
46. Daughton DM, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care: Importance of counseling, demographic and patient selection factors on one-year quit rates. Arch Fam Med. 7:1998;425-430
47. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 164:2001;770-777
48. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 160:1999;542-549
49. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 21:2003;86-94
50. Corsico A, Fulgoni P, Beccaria M, et al. Effects of exercise and beta 2-agonists on lung function in chronic obstructive pulmonary disease. J Appl Physiol. 93:2002;2053-2058
51. Rennard SI, Calverley P. Rescue! therapy and the paradox of the barcalounger. Eur Respir J. 21:2003;916-917
52. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J. 20:2002;799-805
53. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 121:(suppl 5):2002;121-126
54. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in COPD: a retrospective analysis of data from seven clinical trials. Chest. 110:1996;62-70
55. Rosenborg J, Larsson P, Nyberg L. Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults. Br J Clin Pharmacol. 49:2000;199-206
56. Zarkovic JP, Marenk M, Valovirta E, et al. One-year safety study with bambuterol once daily and terbutaline three times daily in 2-12-year-old children with asthma: the bambuterol multicentre study group. Pediatr Pulmonol. 29:2000;424-429
57. Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging. 18:2001;441-472
58. Friedman M, Della Cioppa G, Kottakis J. Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature. Pharmacotherapy. 22:2002;1129-1139
59. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 155:1997;1283-1289
60. Liesker JJ, Van De Velde V, Meysman M, Vincken W, Wollmer P, Hansson L, et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med. 96:2002;559-566
61. Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest. 120:2001;258-270
62. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 115:1999;957-965
63. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 361:2003;449-456
64. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 164:2001;778-784
65. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 21:2003;74-81
66. Ullman A, Lofdahl CG, Melander B, Svedmyr N. Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study. Allergy. 51:1996;745-748
67. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE. 2001:2001;15
68. Rennard SI. Anticholinergic bronchodilators. Martin RJ, Kraft M. Combination therapy for asthma and chronic obstructive pulmonary disease. 2000;159-180 Marcel Dekker, New York
69. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc). 38:2002;585-600
70. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 161:2000;1136-1142
71. On LS, Boonyongsunchai P, Webb S, Davies L, Calverley PM, Costello RW. Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 163:2001;1320-1325
72. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 19:2002;217-224
73. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 19:2002;209-216
74. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 122:2002;47-55
75. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 167:2003;813-818
76. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 165:2002;1371-1376
77. ZuWallach RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 119:2001;1661-1670
78. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 121:2002;1058-1069
79. Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis. 131:1985;747-751
80. Combivent Inhalational Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest. 105:1994;1411-1419
81. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 15:2000;878-885
82. Bleecker ER, Britt EJ. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med. 91:1991;24-27
83. Bellia V, Foresi A, Bianco S, et al. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Respir Med. 96:2002;881-889
84. Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest. 107:1995;718-723
85. Roffel AF, Meurs H, Zaagsma J. Muscarinic receptors and the lung: relevance to chronic obstructive pulmonary disease and asthma. Barnes PJ, Buist AS. The role of anticholinergics in chronic obstructive pulmonary disease and chronic asthma. 1997;92-125 Gardiner-Caldwell Communications, Cheshire
86. Abdel-Latif AA. Cross talk between cyclic AMP and the polyphosphoinositide signaling cascade in iris sphincter and other nonvascular smooth muscle. Proc Soc Exp Biol Med. 211:1996;163-177
87. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 353:1999;1819-1823
88. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 320:2000;1297-1303
89. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 340:1999;1948-1953
90. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 343:2000;1902-1909
91. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 138:2003;969-973
92. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 166:2002;1084-1091
93. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 21:2003;68-73
94. Albert R, Martin T, Lewis S. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Int Med. 92:1980;753-758
95. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 340:1999;1941-1947
96. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 154:1996;407-412
97. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 354:1999;456-460
98. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 164:2001;580-584
99. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 20:2002;819-825
100. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 168:2003;49-53
101. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med. 168:2003;1488-1494
102. Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J. 19:2002;1058-1063
103. Kristufek P, Levine B, Till D, Byrne A. Inhaled formoterol improves lung function in patients with both reversible and poorly reversible COPD. Am J Respir Crit Care Med. 163:2001;280
104. Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J. 17:2001;337-342
105. Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 152:1995;77-120
106. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 58:2003;654-658
107. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 124:2003;834-843
108. Griffin MR, Coffey CS, Neuzil KM, Mitchel EF Jr, Wright PF, Edwards KM. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med. 162:2002;1229-1236
109. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 331:1994;778-784
110. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 169:1994;68-76
111. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA. 273:1995;957-960
112. Black P, Staykova T, Chacko E, Ram FS, Poole P. Prophylactic antibiotic therapy for chronic bronchitis (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
113. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med. 106:1987;196-204
114. Murphy T, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 146:1992;1067-1083
115. American College of Chest Physicians and American Association of Cardiovascular and Pulmonary Rehabilitation guidelines panel. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. Chest 1997; 112: 1363-1396.
116. Sassi-Dambron DE, Eakin EG, Ries AL, Kaplan RM. Treatment of dyspnea in COPD. Chest. 107:1995;724-729
117. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob Res. 1:(suppl 2):1999;51-57
118. Schols AM, Mostert R, Soeters PB, Wouters EF. Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax. 46:1991;695-699
119. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax. 57:2002;1067-1070
120. Gosselink R, Troosters T, Decramer M. Distribution of muscle weakness in patients with stable chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 20:2000;353-360
121. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 153:1996;976-980
122. Saey D, Debigare R, LeBlanc P, et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 168:2003;425-430
123. Meyer PA, Mannino DM, Redd SC, Olson DR. Characteristics of adults dying with COPD. Chest. 122:2002;2003-2008
124. Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J. 20:2002;539-544
125. Clary GL, Palmer SM, Doraiswamy PM. Mood disorders and chronic obstructive pulmonary disease: current research and future needs. Curr Psychiatry Rep. 4:2002;213-221
126. Brenes GA. Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med. 65:2003;963-970
127. Singer HK, Ruchinskas RA, Riley KC, Broshek DK, Barth JT. The psychological impact of end-stage lung disease. Chest. 120:2001;1246-1252
128. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry. 15:2000;1090-1096
129. Borson S, Claypoole K, McDonald GJ. Depression and Chronic Obstructive Pulmonary Disease: Treatment Trials. Semin Clin Neuropsychiatry. 3:1998;115-130
130. Borak J, Chodosowska E, Matuszewski A, Zielinski J. Emotional status does not alter exercise tolerance in patients with chronic obstructive pulmonary disease. Eur Respir J. 12:1998;370-373
131. Yohannes AM, Baldwin RC, Connolly MJ. Prevalence of sub-threshold depression in elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 18:2003;412-416
132. Franco-Bronson K. The management of treatment-resistant depression in the medically ill. Psychiatr Clin North Am. 19:1996;329-350
133. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, Van Tuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 33:1992;190-201
134. Argyropoulou P, Patakas D, Koukou A, Vasiliadis P, Georgopoulos D. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration. 60:1993;216-220
135. Rose C, Wallace L, Dickson R, et al. The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): a systematic review. Patient Educ Couns. 47:2002;311-318
136. de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 84:2003;1154-1157